Borregaard’s operating revenues rose to NOK 1,833 million in Q4 2025, with EBITDA at NOK 405 million. BioMaterials saw growth, while BioSolutions and Fine Chemicals had lower results. Impairments of NOK 245 million were made on bio-based start-ups. Profit before tax was NOK -28 million, with earnings per share at NOK -0.81.

In 2025, Borregaard reported operating revenues of NOK 7,713 million, with EBITDA at NOK 1,878 million. BioSolutions and BioMaterials improved, while Fine Chemicals decreased. Profit before tax was NOK 864 million, with earnings per share at NOK 6.22. CEO Foss-Jacobsen attributed the success to strong business momentum.

CEO Foss-Jacobsen expressed satisfaction with Borregaard’s all-time high EBITDA in 2025, despite challenges like bioethanol price declines. For further information, contact Director Investor Relations, Pål Espen Ramberg, or Director Communications, Tone Horvei Bredal.

This announcement contains inside information under the EU Market Abuse Regulation and is subject to disclosure requirements under the Norwegian Securities Trading Act. Published by Investor Relations Officer Lotte Kvinlaug on February 4, 2026, at 07:00 CET.

Read more at GlobeNewswire: EBITDA1 of NOK 405 million in the 4th